Which has stronger valuation and earnings, ANAB or VALN?

AnaptysBio has higher revenue and earnings than Valneva. AnaptysBio is trading at a lower price-to-earnings ratio than Valneva, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AnaptysBio $234.60M 8.81 -$13.23M -$1.08 N/A Valneva $197.56M 2.53 -$130.33M -$1.87 N/A

Is ANAB or VALN more profitable?

AnaptysBio has a net margin of -11.53% compared to Valneva's net margin of -88.87%. AnaptysBio's return on equity of 0.00% beat Valneva's return on equity. Company Net Margins Return on Equity Return on Assets AnaptysBio -11.53% N/A -7.75% Valneva -88.87% -107.63% -33.02%

Does the media prefer ANAB or VALN?

In the previous week, Valneva had 2 more articles in the media than AnaptysBio. MarketBeat recorded 5 mentions for Valneva and 3 mentions for AnaptysBio. AnaptysBio's average media sentiment score of 1.08 beat Valneva's score of 0.44 indicating that AnaptysBio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AnaptysBio 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Valneva 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings and valuation, VALN or NUVB?

Valneva has higher revenue and earnings than Nuvation Bio. Nuvation Bio is trading at a lower price-to-earnings ratio than Valneva, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Valneva $197.56M 2.53 -$130.33M -$1.87 N/A Nuvation Bio $62.90M 31.97 -$204.63M -$0.43 N/A

Is VALN or NUVB more profitable?

Valneva has a net margin of -88.87% compared to Nuvation Bio's net margin of -102.06%. Nuvation Bio's return on equity of -44.10% beat Valneva's return on equity. Company Net Margins Return on Equity Return on Assets Valneva -88.87% -107.63% -33.02% Nuvation Bio -102.06% -44.10% -23.80%

Does the media favor VALN or NUVB?

In the previous week, Valneva and Valneva both had 5 articles in the media. Nuvation Bio's average media sentiment score of 0.60 beat Valneva's score of 0.44 indicating that Nuvation Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Valneva 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Nuvation Bio 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings and valuation, VALN or PGEN?

Valneva has higher revenue and earnings than Precigen. Precigen is trading at a lower price-to-earnings ratio than Valneva, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Valneva $197.56M 2.53 -$130.33M -$1.87 N/A Precigen $9.68M 190.41 -$250.64M -$1.18 N/A

Is VALN or PGEN more profitable?

Valneva has a net margin of -88.87% compared to Precigen's net margin of -646.99%. Precigen's return on equity of 717.50% beat Valneva's return on equity. Company Net Margins Return on Equity Return on Assets Valneva -88.87% -107.63% -33.02% Precigen -646.99% 717.50% 58.48%

Does the media refer more to VALN or PGEN?

In the previous week, Valneva had 2 more articles in the media than Precigen. MarketBeat recorded 5 mentions for Valneva and 3 mentions for Precigen. Precigen's average media sentiment score of 1.18 beat Valneva's score of 0.44 indicating that Precigen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Valneva 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Precigen 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation and earnings, NBTX or VALN?

Nanobiotix has higher earnings, but lower revenue than Valneva. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nanobiotix $36.87M 53.75 -$27.11M N/A N/A Valneva $197.56M 2.53 -$130.33M -$1.87 N/A

Is NBTX or VALN more profitable?

Nanobiotix has a net margin of 0.00% compared to Valneva's net margin of -88.87%. Nanobiotix's return on equity of 0.00% beat Valneva's return on equity. Company Net Margins Return on Equity Return on Assets Nanobiotix N/A N/A N/A Valneva -88.87% -107.63% -33.02%

Does the media favor NBTX or VALN?

In the previous week, Valneva had 2 more articles in the media than Nanobiotix. MarketBeat recorded 5 mentions for Valneva and 3 mentions for Nanobiotix. Nanobiotix's average media sentiment score of 0.91 beat Valneva's score of 0.44 indicating that Nanobiotix is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nanobiotix 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Valneva 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher earnings & valuation, VALN or ANIP?

ANI Pharmaceuticals has higher revenue and earnings than Valneva. Valneva is trading at a lower price-to-earnings ratio than ANI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Valneva $197.56M 2.53 -$130.33M -$1.87 N/A ANI Pharmaceuticals $883.37M 2.09 $78.34M $3.95 20.53

Does the media refer more to VALN or ANIP?

In the previous week, ANI Pharmaceuticals had 8 more articles in the media than Valneva. MarketBeat recorded 13 mentions for ANI Pharmaceuticals and 5 mentions for Valneva. ANI Pharmaceuticals' average media sentiment score of 0.50 beat Valneva's score of 0.44 indicating that ANI Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Valneva 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ANI Pharmaceuticals 6 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Valneva (VALN) Competitors

$5.26 +0.21 (+4.16%)

Closing price 07/13/2026 04:00 PM Eastern

Extended Trading

$5.30 +0.04 (+0.67%)

As of 07/13/2026 04:10 PM Eastern

Compare

VALN vs. ANAB, NUVB, PGEN, NBTX, and ANIP

Should you buy Valneva stock or one of its competitors? MarketBeat compares Valneva with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Valneva include AnaptysBio (ANAB), Nuvation Bio (NUVB), Precigen (PGEN), Nanobiotix (NBTX), and ANI Pharmaceuticals (ANIP). These companies are all part of the "pharmaceutical products" industry.

How does Valneva compare to AnaptysBio?

AnaptysBio (NASDAQ:ANAB) and Valneva (NASDAQ:VALN) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, institutional ownership, valuation, dividends, risk, media sentiment and earnings.

In the previous week, Valneva had 2 more articles in the media than AnaptysBio. MarketBeat recorded 5 mentions for Valneva and 3 mentions for AnaptysBio. AnaptysBio's average media sentiment score of 1.08 beat Valneva's score of 0.44 indicating that AnaptysBio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AnaptysBio	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Valneva	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

AnaptysBio has higher revenue and earnings than Valneva. AnaptysBio is trading at a lower price-to-earnings ratio than Valneva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AnaptysBio	$234.60M	8.81	-$13.23M	-$1.08	N/A
Valneva	$197.56M	2.53	-$130.33M	-$1.87	N/A

AnaptysBio has a beta of 0.68, meaning that its share price is 32% less volatile than the broader market. Comparatively, Valneva has a beta of 1.77, meaning that its share price is 77% more volatile than the broader market.

AnaptysBio has a net margin of -11.53% compared to Valneva's net margin of -88.87%. AnaptysBio's return on equity of 0.00% beat Valneva's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AnaptysBio	-11.53%	N/A	-7.75%
Valneva	-88.87%	-107.63%	-33.02%

AnaptysBio currently has a consensus price target of $81.82, suggesting a potential upside of 17.20%. Valneva has a consensus price target of $11.98, suggesting a potential upside of 127.66%. Given Valneva's higher possible upside, analysts clearly believe Valneva is more favorable than AnaptysBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AnaptysBio	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69
Valneva	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20

11.4% of Valneva shares are held by institutional investors. 31.5% of AnaptysBio shares are held by company insiders. Comparatively, 14.9% of Valneva shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

AnaptysBio beats Valneva on 11 of the 16 factors compared between the two stocks.

How does Valneva compare to Nuvation Bio?

Valneva (NASDAQ:VALN) and Nuvation Bio (NYSE:NUVB) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, media sentiment, dividends, earnings and risk.

Valneva has a net margin of -88.87% compared to Nuvation Bio's net margin of -102.06%. Nuvation Bio's return on equity of -44.10% beat Valneva's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Valneva	-88.87%	-107.63%	-33.02%
Nuvation Bio	-102.06%	-44.10%	-23.80%

Valneva has a beta of 1.77, indicating that its share price is 77% more volatile than the broader market. Comparatively, Nuvation Bio has a beta of 1.52, indicating that its share price is 52% more volatile than the broader market.

11.4% of Valneva shares are owned by institutional investors. Comparatively, 61.7% of Nuvation Bio shares are owned by institutional investors. 14.9% of Valneva shares are owned by insiders. Comparatively, 30.1% of Nuvation Bio shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Valneva presently has a consensus price target of $11.98, suggesting a potential upside of 127.66%. Nuvation Bio has a consensus price target of $12.38, suggesting a potential upside of 114.29%. Given Valneva's higher possible upside, equities research analysts clearly believe Valneva is more favorable than Nuvation Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Valneva	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20
Nuvation Bio	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

Valneva has higher revenue and earnings than Nuvation Bio. Nuvation Bio is trading at a lower price-to-earnings ratio than Valneva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Valneva	$197.56M	2.53	-$130.33M	-$1.87	N/A
Nuvation Bio	$62.90M	31.97	-$204.63M	-$0.43	N/A

In the previous week, Valneva and Valneva both had 5 articles in the media. Nuvation Bio's average media sentiment score of 0.60 beat Valneva's score of 0.44 indicating that Nuvation Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Valneva	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Nuvation Bio	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Nuvation Bio beats Valneva on 9 of the 15 factors compared between the two stocks.

How does Valneva compare to Precigen?

Valneva (NASDAQ:VALN) and Precigen (NASDAQ:PGEN) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, media sentiment, valuation, dividends, risk and profitability.

11.4% of Valneva shares are owned by institutional investors. Comparatively, 33.5% of Precigen shares are owned by institutional investors. 14.9% of Valneva shares are owned by insiders. Comparatively, 41.4% of Precigen shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Valneva has a beta of 1.77, indicating that its stock price is 77% more volatile than the broader market. Comparatively, Precigen has a beta of 1, indicating that its stock price has a similar volatility profile to the broader market.

Valneva has a net margin of -88.87% compared to Precigen's net margin of -646.99%. Precigen's return on equity of 717.50% beat Valneva's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Valneva	-88.87%	-107.63%	-33.02%
Precigen	-646.99%	717.50%	58.48%

In the previous week, Valneva had 2 more articles in the media than Precigen. MarketBeat recorded 5 mentions for Valneva and 3 mentions for Precigen. Precigen's average media sentiment score of 1.18 beat Valneva's score of 0.44 indicating that Precigen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Valneva	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Precigen	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Valneva currently has a consensus target price of $11.98, suggesting a potential upside of 127.66%. Precigen has a consensus target price of $12.50, suggesting a potential upside of 141.78%. Given Precigen's stronger consensus rating and higher possible upside, analysts plainly believe Precigen is more favorable than Valneva.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Valneva	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20
Precigen	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Valneva has higher revenue and earnings than Precigen. Precigen is trading at a lower price-to-earnings ratio than Valneva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Valneva	$197.56M	2.53	-$130.33M	-$1.87	N/A
Precigen	$9.68M	190.41	-$250.64M	-$1.18	N/A

Summary

Precigen beats Valneva on 9 of the 15 factors compared between the two stocks.

How does Valneva compare to Nanobiotix?

Nanobiotix (NASDAQ:NBTX) and Valneva (NASDAQ:VALN) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, dividends, media sentiment, institutional ownership and risk.

Nanobiotix has higher earnings, but lower revenue than Valneva.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nanobiotix	$36.87M	53.75	-$27.11M	N/A	N/A
Valneva	$197.56M	2.53	-$130.33M	-$1.87	N/A

Nanobiotix currently has a consensus target price of $37.33, suggesting a potential downside of 4.64%. Valneva has a consensus target price of $11.98, suggesting a potential upside of 127.66%. Given Valneva's higher probable upside, analysts clearly believe Valneva is more favorable than Nanobiotix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nanobiotix	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Valneva	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20

Nanobiotix has a net margin of 0.00% compared to Valneva's net margin of -88.87%. Nanobiotix's return on equity of 0.00% beat Valneva's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nanobiotix	N/A	N/A	N/A
Valneva	-88.87%	-107.63%	-33.02%

In the previous week, Valneva had 2 more articles in the media than Nanobiotix. MarketBeat recorded 5 mentions for Valneva and 3 mentions for Nanobiotix. Nanobiotix's average media sentiment score of 0.91 beat Valneva's score of 0.44 indicating that Nanobiotix is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nanobiotix	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Valneva	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

38.8% of Nanobiotix shares are owned by institutional investors. Comparatively, 11.4% of Valneva shares are owned by institutional investors. 3.5% of Nanobiotix shares are owned by insiders. Comparatively, 14.9% of Valneva shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Nanobiotix has a beta of 0.78, suggesting that its stock price is 22% less volatile than the broader market. Comparatively, Valneva has a beta of 1.77, suggesting that its stock price is 77% more volatile than the broader market.

Summary

Nanobiotix beats Valneva on 9 of the 14 factors compared between the two stocks.

How does Valneva compare to ANI Pharmaceuticals?

Valneva (NASDAQ:VALN) and ANI Pharmaceuticals (NASDAQ:ANIP) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, media sentiment, earnings, valuation, institutional ownership, risk and dividends.

ANI Pharmaceuticals has a net margin of 9.98% compared to Valneva's net margin of -88.87%. ANI Pharmaceuticals' return on equity of 27.51% beat Valneva's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Valneva	-88.87%	-107.63%	-33.02%
ANI Pharmaceuticals	9.98%	27.51%	10.02%

Valneva has a beta of 1.77, indicating that its stock price is 77% more volatile than the broader market. Comparatively, ANI Pharmaceuticals has a beta of 0.43, indicating that its stock price is 57% less volatile than the broader market.

Valneva presently has a consensus target price of $11.98, suggesting a potential upside of 127.66%. ANI Pharmaceuticals has a consensus target price of $107.33, suggesting a potential upside of 32.38%. Given Valneva's higher possible upside, analysts plainly believe Valneva is more favorable than ANI Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Valneva	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20
ANI Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.75

11.4% of Valneva shares are owned by institutional investors. Comparatively, 76.1% of ANI Pharmaceuticals shares are owned by institutional investors. 14.9% of Valneva shares are owned by company insiders. Comparatively, 8.1% of ANI Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

ANI Pharmaceuticals has higher revenue and earnings than Valneva. Valneva is trading at a lower price-to-earnings ratio than ANI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Valneva	$197.56M	2.53	-$130.33M	-$1.87	N/A
ANI Pharmaceuticals	$883.37M	2.09	$78.34M	$3.95	20.53

In the previous week, ANI Pharmaceuticals had 8 more articles in the media than Valneva. MarketBeat recorded 13 mentions for ANI Pharmaceuticals and 5 mentions for Valneva. ANI Pharmaceuticals' average media sentiment score of 0.50 beat Valneva's score of 0.44 indicating that ANI Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Valneva	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ANI Pharmaceuticals	6 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

ANI Pharmaceuticals beats Valneva on 12 of the 16 factors compared between the two stocks.

Get Valneva News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VALN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VALN vs. The Competition

Export

Metric	Valneva	MED PRODUCTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$479.17M	$8.82B	$7.05B	$12.61B
Dividend Yield	N/A	2.54%	2.68%	8.00%
P/E Ratio	-2.81	16.09	27.12	24.26
Price / Sales	2.53	7.04	587.25	117.88
Price / Cash	N/A	18.40	29.22	49.36
Price / Book	3.78	3.57	10.89	6.29
Net Income	-$130.33M	$228.19M	$3.58B	$330.66M
7 Day Performance	N/A	-2.31%	-2.11%	-1.35%
1 Month Performance	-1.87%	-0.62%	3.28%	-0.64%
1 Year Performance	-16.77%	-2.73%	26.33%	19.08%

Valneva Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VALN Valneva	2.3479 of 5 stars	$5.26 +4.2%	$11.98 +127.7%	-13.3%	$479.17M	$197.56M	N/A	700	Gap Up
ANAB AnaptysBio	2.1788 of 5 stars	$67.32 +8.0%	$81.82 +21.5%	+166.5%	$1.99B	$234.60M	N/A	100	Positive News
NUVB Nuvation Bio	3.3193 of 5 stars	$5.68 +1.3%	$12.38 +118.1%	+162.5%	$1.98B	$62.90M	N/A	60
PGEN Precigen	3.1671 of 5 stars	$5.51 -1.6%	$12.50 +126.9%	+182.5%	$1.96B	$9.68M	N/A	190	Positive News
NBTX Nanobiotix	2.002 of 5 stars	$38.80 -5.6%	$37.33 -3.8%	+642.9%	$1.96B	$36.87M	N/A	100

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VALN) was last updated on 7/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Valneva (VALN) Competitors